Roche statement on casirivimab and imdevimab data in preventing COVID-19 infections within households

Basel, 26 January 2021

On 26 January 2021, Regeneron communicated positive initial results from an ongoing phase III clinical trial (REGN-COV2 2069) evaluating its investigational antibody cocktail of casirivimab and imdevimab for the prevention of COVID-19 in over 2,000 people at high risk of infection, due to household exposure to a COVID-19 positive person. The trial is being run jointly with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

These data are from an exploratory analysis across 409 seronegative patients (those without COVID-19 antibodies) who were randomised to receive casirivimab and imdevimab as a post-exposure prophylactic (1,200 mg via subcutaneous injections) or placebo. The data showed that there was a reduction in overall infections seen with casirivimab and imdevimab within the first week, with approximately 50% lower overall rates of infection (symptomatic and asymptomatic) and 100% prevention of symptomatic infections. In the safety assessment of these patients, adverse events occurred more frequently in participants on placebo (10% in the casirivimab and imdevimab group and 20% in the placebo group); it is believed this difference was driven by the increased rate of SARS-CoV-2 infections in the placebo group.

We are encouraged by these initial results, which showed that casirivimab and imdevimab may both reduce household infection of the virus as well as decrease clinical disease burden in those who still get infected. This combination of two different antibodies in one cocktail may prevent potential future mutant SARS-CoV-2 variants from resistance. Additionally, the subcutaneous administration may allow more patients to benefit if the antibody cocktail is approved.

In addition to this study, casirivimab and imdevimab are currently being studied in a phase II/III clinical trial for the treatment of COVID-19 in non-hospitalised patients and a phase II/III trial for the treatment of COVID-19 in hospitalised patients, both administered intravenously.

In August, Roche and Regeneron announced a collaboration in the fight against COVID-19 to develop, manufacture and distribute casirivimab and imdevimab, Regeneron’s investigational antiviral neutralising antibody cocktail, to people around the globe. Casirivimab and imdevimab could provide a much-needed treatment option for infected individuals already experiencing symptoms of COVID-19, and may be able to prevent infection in people exposed to the virus, and hopefully to help slow the spread of the global pandemic.
Roche is partnering closely with governments and health authorities across the globe in a concerted effort to bring casirivimab and imdevimab to as many patients as possible. The first of these agreements was with the German government, allowing early access of casirivimab and imdevimab prior to health authority approval.

In these exceptional times, Roche stands together with society, governments, healthcare providers and all those working to overcome the pandemic.

**About casirivimab and imdevimab**
Casirivimab and imdevimab is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed by Regeneron scientists to block infectivity of SARS-CoV-2, the virus that causes COVID-19. They evaluated thousands of fully-human antibodies produced by the company’s proprietary VelocImmune® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.

The two potent, virus-neutralising antibodies that form casirivimab and imdevimab are believed to bind non-competitively to the critical receptor binding domain of the virus’s spike protein, which is hypothesised to diminish the ability of mutant viruses to escape treatment and to protect against spike variants that may arise in the human population, as detailed in recent *Science* publications.

Casirivimab and imdevimab’s development, manufacturing and clinical trials have been funded in part by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services under OT number: HHSO100201700020C.

**About Emergency Use Authorization status**
Casirivimab and imdevimab have not been Food and Drug Administration (FDA) cleared or approved in the United States (US). They have been authorised by the FDA under an Emergency Use Authorization (EUA) during the current public health emergency for the treatment of mild to moderate COVID-19 in adults and paediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalisation. Please see the [Fact Sheet for Healthcare Providers](#) for more information, including important safety information. The cocktail is only authorised for the duration of the declaration that circumstances exist justifying the authorisation of the emergency use under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorisation revoked sooner.

**About Roche’s response to the COVID-19 pandemic**
As a leading healthcare company we are doing all we can to support countries in minimising the impact of COVID-19. We have developed a growing number of diagnostic solutions that help to detect and diagnose the infection in patients, as well as providing digital support to healthcare systems, and we continue to identify, develop and support potential therapies which can play a role in treating the disease.
We understand the impact of COVID-19 goes beyond those who contract it, which is why we are working with healthcare providers, laboratories, authorities and organisations to help make sure that patients continue to receive the tests, treatment and care they need during these challenging times. As we learn from the pandemic, we are partnering with governments and others to make healthcare stronger and more sustainable in the future.

**Our diagnostics solutions:**
Reliable, high-quality testing is essential to help healthcare systems overcome this pandemic. Our portfolio includes:

- a high-volume molecular test to detect SARS-CoV-2, the virus that causes COVID-19, (FDA Emergency Use Authorisation (EUA) and available in countries accepting the CE Mark)
- a SARS-CoV-2 laboratory-based antibody test, aimed at detecting the presence of antibodies in the blood targeting the nucleocapsid (FDA EUA and CE Mark)
- an IL-6 test to assist in identifying severe inflammatory response in patients with confirmed COVID-19 (FDA EUA and CE Mark)
- Roche v-TAC, which could help simplify the screening, diagnosis and monitoring of patients with respiratory compromise in the current COVID-19 pandemic
- a SARS-CoV-2 rapid antibody test to help determine at the point of care whether a person has been exposed to the virus (CE Mark)
- a rapid antigen test to support in the detection of SARS-CoV-2 at the point of care within 15 minutes (CE Mark)
- a high-volume molecular test to simultaneously detect and differentiate between SARS-CoV-2 and influenza A/B, as the symptoms are similar for both (FDA EUA and CE Mark)
- a second SARS-CoV-2 antibody test, aimed at measuring the spike protein to support vaccination development and complement our existing portfolio
- a point-of-care molecular PCR test that simultaneously detects and differentiates between SARS-CoV-2 and influenza A/B infections to support urgent triage and diagnosis (FDA EUA and CE Mark)

**Our research into therapies:**

Roche is committed to improving the treatment of COVID-19. We are actively involved in understanding the potential of our existing portfolio and are exploring the potential of our investigational molecules.

There have been/are a number of clinical trials with an external 3rd party as the sponsor exploring the efficacy and safety of Actemra (tocilizumab) for the treatment of COVID-19 associated pneumonia. COVACTA and EMPACTA, sponsored by Roche, are the first global phase III, multi-centre, randomised, placebo-controlled studies evaluating Actemra in this setting.
We continue to evaluate the data from the global COVACTA study, which did not meet its primary endpoint as announced on 29 July 2020, in conjunction with results from the global EMPACTA study of Actemra in COVID-19 pneumonia, which met its primary endpoint as announced on 17 September 2020, as well as additional data sources that are in the public domain to determine whether a population can be defined based on patient and disease characteristics in which Actemra on top of usual care may provide a favourable benefit risk profile.

Roche remains committed to continuing the Actemra clinical trial programme in COVID-19 to further explore Actemra in other treatment settings, including in combination with an antiviral.

In August 2020 we signed a collaboration agreement with Regeneron on developing, manufacturing and significantly increasing global supply of an investigational antibody cocktail for COVID-19 if it proves safe and effective in clinical trials and regulatory approvals are granted.

In October 2020 we signed an agreement with Atea to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in phase II clinical trials. AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting, as well as in the hospital, and may also be used in post-exposure prophylactic settings.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the
majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit [www.roche.com](http://www.roche.com).

All trademarks used or mentioned in this release are protected by law.

**Roche Group Media Relations**
Phone: +41 61 688 8888 / e-mail: [media.relations@roche.com](mailto:media.relations@roche.com)

- Dr. Nicolas Dunant
  Phone: +41 61 687 05 17

- Daniel Grotzky
  Phone: +41 61 688 31 10

- Nina Mählitz
  Phone: +41 79 327 54 74

- Barbara von Schnurbein
  Phone: +41 61 687 89 67

- Patrick Barth
  Phone: +41 61 688 44 86

- Karsten Kleine
  Phone: +41 61 682 28 31

- Nathalie Meetz
  Phone: +41 61 687 43 05

**Roche Investor Relations**

- Dr. Karl Mahler
  Phone: +41 61 68-78503
  e-mail: [karl.mahler@roche.com](mailto:karl.mahler@roche.com)

- Dr. Sabine Borngräber
  Phone: +41 61 68-88027
  e-mail: [sabine.borngraebroche.com](mailto:sabine.borngraebroche.com)

- Dr. Birgit Masjost
  Phone: +41 61 68-84814
  e-mail: [birgit.masjost@roche.com](mailto:birgit.masjost@roche.com)

- Jon Kaspar Bayard
  Phone: +41 61 68-83894
  e-mail: [jon_kaspar.bayard@roche.com](mailto:jon_kaspar.bayard@roche.com)

- Dr. Bruno Eschli
  Phone: +41 61 68-75284
  e-mail: [bruno.eschli@roche.com](mailto:bruno.eschli@roche.com)

- Dr. Gerard Tobin
  Phone: +41 61 68-72942
  e-mail: [gerard.tobin@roche.com](mailto:gerard.tobin@roche.com)

**Investor Relations North America**

- Loren Kalm
  Phone: +1 650 225 3217
  e-mail: [kalm.loren@gene.com](mailto:kalm.loren@gene.com)

- Dr. Lisa Tuomi
  Phone: +1 650 467 8737
  e-mail: [tuomi.lisa@gene.com](mailto:tuomi.lisa@gene.com)